Talquetamab, a Novel Anti-Myeloma GPRC5DxCD3 Bispecific Antibody, is Associated with Increased Oropharyngeal FDG Uptake

被引：0
|
作者：
Trak, J. [1 ]
Mouhieddine, T. [1 ]
Lancman, G. [1 ]
Sanchez, L. [1 ]
Chari, A. [1 ]
Ghesani, M. [1 ]
机构：
[1] Mt Sinai Hosp, New York, NY USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0351
引用
收藏
页码：S571 / S571
页数：1
相关论文
共 50 条
  • [21] Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
    Dekhtiarenko, Iryna
    Lelios, Iva
    Attig, Jan
    Sleiman, Nassim
    Lazzaro, Domenico
    Schindler, Emilie
    Eckmann, Jan
    Umana, Pablo
    Jacob, Wolfgang
    Schneider, Meike
    Carlo-Stella, Carmelo
    Mazza, Rita
    Manier, Salomon
    Facon, Thierry
    Yoon, Sung-Soo
    Koh, Youngil
    Harrison, Simon J.
    Er, Jeremy
    Pinto, Antonio
    Volzone, Francesco
    Perrone, Giulia
    Corradini, Paolo
    Cazaubiel, Titouan
    Hulin, Cyrille
    Touzeau, Cyrille
    Moreau, Philippe
    Ocio, Enrique M.
    Gaisan, Carmen Maria Montes
    Popat, Rakesh
    Leong, Sarah
    Offner, Fritz
    Otero, Paula Rodriguez
    Alfonso-Pierola, Ana
    Hutchings, Martin
    Riley, Caroline Hasselbalch
    Broske, Ann-Marie E.
    BLOOD, 2022, 140 : 10137 - 10139
  • [22] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    A. M. G. A. Laheij
    N. W. C. J. van de Donk
    Supportive Care in Cancer, 2024, 32
  • [23] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    Laheij, A. M. G. A.
    van de Donk, N. W. C. J.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
  • [24] Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody
    Dekhtiarenko, Iryna
    Lelios, Iva
    Jacob, Wolfgang
    Schneider, Meike
    Weisser, Martin
    Carlo-Stella, Carmelo
    Manier, Salomon
    Harrison, Simon J.
    Popat, Rakesh
    Riley, Anna Caroline Hasselbalch
    Broeke, Ann-Marie E.
    BLOOD, 2023, 142
  • [25] Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma
    Kodama, Tatsushi
    Kochi, Yu
    Nakai, Waka
    Mizuno, Hideaki
    Baba, Takeshi
    Habu, Kiyoshi
    Sawada, Noriaki
    Tsunoda, Hiroyuki
    Shima, Takahiro
    Miyawaki, Kohta
    Kikushige, Yoshikane
    Mori, Yasuo
    Miyamoto, Toshihiro
    Maeda, Takahiro
    Akashi, Koichi
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (09) : 1555 - 1564
  • [26] Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myeloma
    Aronson, Elizabeth
    Purcell, Kiah
    Aponte, Annel
    Louw, Karen
    Catamero, Donna
    Lamb, Angela
    Kirke, Diana
    Lucas, Aimee
    Jagannath, Sundar
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S195 - S195
  • [27] A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
    Urara Tomita
    Yoko Ishimoto
    Masaki Ri
    Yumi Kawase
    Yoshiyuki Hizukuri
    Chikako Maru
    Kayoko Nanai
    Ryuichi Nakamura
    Makiko Nakayama
    Keiko Oguchi-Oshima
    Hiroyuki Sumi
    Toshiaki Ohtsuka
    Shinsuke Iida
    Toshinori Agatsuma
    Scientific Reports, 14
  • [28] Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gill, Sarvarinder Kaur
    Fleming, Erika
    Gebre, Helen
    Bangolo, Ayrton, I
    Siegel, David S.
    Vesole, David H.
    Biran, Noa
    Parmar, Harsh
    Phull, Pooja
    BLOOD, 2024, 144 : 7047 - 7048
  • [29] A novel T cell-redirecting anti-GPRC5D x CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
    Tomita, Urara
    Ishimoto, Yoko
    Ri, Masaki
    Kawase, Yumi
    Hizukuri, Yoshiyuki
    Maru, Chikako
    Nanai, Kayoko
    Nakamura, Ryuichi
    Nakayama, Makiko
    Oguchi-Oshima, Keiko
    Sumi, Hiroyuki
    Ohtsuka, Toshiaki
    Iida, Shinsuke
    Agatsuma, Toshinori
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [30] RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
    Carlo-Stella, Carmelo
    Mazza, Rita
    Manier, Salomon
    Facon, Thierry
    Yoon, Sung-Soo
    Koh, Youngil
    Harrison, Simon J.
    Er, Jeremy
    Pinto, Antonio
    Volzone, Francesco
    Perrone, Giulia
    Corradini, Paolo
    Cazaubiel, Titouan
    Hulin, Cyrille
    Touzeau, Cyrille
    Moreau, Philippe
    Ocio, Enrique M.
    Gaisan, Carmen Maria Montes
    Popat, Rakesh
    Leong, Sarah
    Offner, Fritz
    Otero, Paula Rodriguez
    Alfonso-Pierola, Ana
    Broeske, Ann-Marie E.
    Dekhtiarenko, Iryna
    Helms, Hans-Joachim
    Belli, Sara
    Rossmann, Eva
    Fauti, Tanja
    Eckmann, Jan
    Moore, Tom
    Schneider, Meike
    Jacob, Wolfgang
    Weisser, Martin
    Hutchings, Martin
    Riley, Caroline Hasselbalch
    BLOOD, 2022, 140
12345